MedPath

Desloratadine

Generic Name
Desloratadine
Brand Names
Aerius, Clarinex, Clarinex-D, Neoclarityn, Desloratadine ratiopharm, Desloratadine Teva, Desloratadine Actavis, Dasselta, Azomyr
Drug Type
Small Molecule
Chemical Formula
C19H19ClN2
CAS Number
100643-71-8
Unique Ingredient Identifier
FVF865388R
Background

Desloratadine is a second generation, tricyclic antihistamine that which has a selective and peripheral H1-antagonist action. It is the active descarboethoxy metabolite of loratidine (a second generation histamine). Desloratidine has a long-lasting effect and does not cause drowsiness because it does not readily enter the central nervous system.

Indication

For the relief of symptoms of seasonal allergic rhinitis, perennial (non-seasonal) allergic rhinitis. Desloratidine is also used for the sympomatic treatment of pruritus and urticaria (hives) associated with chronic idiopathic urticaria.

Associated Conditions
Allergic Rhinitis (AR), Asthma, Chronic Idiopathic Urticaria, Common Cold, Nasal Congestion, Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis, Nasal symptoms, Non-nasal symptoms
Associated Therapies
Antihistamine

Taste Test Between Desloratadine and Cetirizine Syrup in Children (Study P03829)(COMPLETED)

Phase 3
Completed
Conditions
Allergic Rhinitis
Interventions
First Posted Date
2008-11-20
Last Posted Date
2022-02-16
Lead Sponsor
Organon and Co
Target Recruit Count
202
Registration Number
NCT00794378

Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03182)

Phase 4
Completed
Conditions
Perennial Allergic Rhinitis
Seasonal Allergic Rhinitis
Interventions
First Posted Date
2008-11-20
Last Posted Date
2022-02-17
Lead Sponsor
Organon and Co
Target Recruit Count
118
Registration Number
NCT00794599

Preference for Clarinex Tablets vs. Allegra Tablets in Patients With Seasonal Allergies (Study P03179)

Phase 4
Completed
Conditions
Seasonal Allergic Rhinitis
Interventions
First Posted Date
2008-11-20
Last Posted Date
2022-02-17
Lead Sponsor
Organon and Co
Target Recruit Count
122
Registration Number
NCT00794248

The Effect of Desloratadine and Levocetirizine on Nasal Obstruction (Study P03609)

Phase 3
Completed
Conditions
Allergic Rhinitis
Interventions
First Posted Date
2008-11-11
Last Posted Date
2024-08-15
Lead Sponsor
Organon and Co
Target Recruit Count
81
Registration Number
NCT00789152

Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR)(Study P04053)(COMPLETED)

Phase 4
Completed
Conditions
Seasonal Allergic Rhinitis
Interventions
First Posted Date
2008-10-31
Last Posted Date
2024-08-15
Lead Sponsor
Organon and Co
Target Recruit Count
722
Registration Number
NCT00783211

Preference for Clarinex Tablets vs. Allegra Tablets in Patients With Seasonal Allergies (Study P03177)

Phase 4
Completed
Conditions
Seasonal Allergic Rhinitis
Interventions
First Posted Date
2008-10-31
Last Posted Date
2024-08-15
Lead Sponsor
Organon and Co
Target Recruit Count
131
Registration Number
NCT00783133

Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR) (Study P04054)

Phase 4
Completed
Conditions
Seasonal Allergic Rhinitis
Interventions
First Posted Date
2008-10-31
Last Posted Date
2024-08-15
Lead Sponsor
Organon and Co
Target Recruit Count
728
Registration Number
NCT00783146

A Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiopathic Urticaria (Study P03147)

Phase 4
Completed
Conditions
Urticaria
Chronic Idiopathic Urticaria
Interventions
First Posted Date
2008-10-31
Last Posted Date
2024-08-15
Lead Sponsor
Organon and Co
Target Recruit Count
129
Registration Number
NCT00783354

Multi-Center, Pediatric, Open-Label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec ® 5.0 mg Chewable Tablet Medications (Study P04573) (Completed)

Phase 4
Completed
Conditions
Allergies
Interventions
First Posted Date
2008-10-27
Last Posted Date
2022-02-09
Lead Sponsor
Organon and Co
Target Recruit Count
220
Registration Number
NCT00780403

Effectiveness and Safety of Desloratadine in Patients With Allergic Airway Disease During the Pollen Season (Study P03284)

Phase 4
Completed
Conditions
Allergic Airway Disease
Interventions
Drug: Placebo
First Posted Date
2008-10-24
Last Posted Date
2024-08-15
Lead Sponsor
Organon and Co
Target Recruit Count
506
Registration Number
NCT00779636
© Copyright 2025. All Rights Reserved by MedPath